About
Technology
Issues
FAQ
Links
Official Page
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.